Literature DB >> 26995208

MR imaging features and staging of neuroendocrine carcinomas of the uterine cervix with pathological correlations.

Xiaohui Duan1, Xiaohua Ban2, Xiang Zhang1, Huijun Hu1, Guozhao Li1, Dongye Wang1, Charles Qian Wang1,3, Fang Zhang1, Jun Shen4.   

Abstract

OBJECTIVE: To determine MR imaging features and staging accuracy of neuroendocrine carcinomas (NECs) of the uterine cervix with pathological correlations.
METHODS: Twenty-six patients with histologically proven NECs, 60 patients with squamous cell carcinomas (SCCs), and 30 patients with adenocarcinomas of the uterine cervix were included. The clinical data, pathological findings, and MRI findings were reviewed retrospectively. MRI features of cervical NECs, SCCs, and adenocarcinomas were compared, and MRI staging of cervical NECs was compared with the pathological staging.
RESULTS: Cervical NECs showed a higher tendency toward a homogeneous signal intensity on T2-weighted imaging and a homogeneous enhancement pattern, as well as a lower ADC value of tumour and a higher incidence of lymphadenopathy, compared with SCCs and adenocarcinomas (P < 0.05). An ADC value cutoff of 0.90 × 10-3 mm2/s was robust for differentiation between cervical NECs and other cervical cancers, with a sensitivity of 63.3 % and a specificity of 95 %. In 21 patients who underwent radical hysterectomy and lymphadenectomy, the overall accuracy of tumour staging by MR imaging was 85.7 % with reference to pathology staging.
CONCLUSION: Homogeneous lesion texture and low ADC value are likely suggestive features of cervical NECs and MR imaging is reliable for the staging of cervical NECs. KEY POINTS: • Cervical NECs show a tendency of lesion homogeneity and lymphadenopathy • Low ADC values are found in cervical NECs • MRI is an accurate imaging modality for the cervical NEC staging.

Entities:  

Keywords:  Cervical cancer; Diffusion-weighted imaging; Magnetic resonance imaging; Neoplasm staging; Neuroendocrine tumours

Mesh:

Year:  2016        PMID: 26995208     DOI: 10.1007/s00330-016-4327-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix.

Authors:  D M Boruta; J O Schorge; L A Duska; C P Crum; D H Castrillon; E E Sheets
Journal:  Gynecol Oncol       Date:  2001-04       Impact factor: 5.482

2.  Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology.

Authors:  Corinne Balleyguier; E Sala; T Da Cunha; A Bergman; B Brkljacic; F Danza; R Forstner; B Hamm; R Kubik-Huch; C Lopez; R Manfredi; J McHugo; L Oleaga; K Togashi; K Kinkel
Journal:  Eur Radiol       Date:  2010-11-10       Impact factor: 5.315

Review 3.  PET/CT and MRI in the imaging assessment of cervical cancer.

Authors:  Joanna Kusmirek; Jessica Robbins; Hailey Allen; Lisa Barroilhet; Bethany Anderson; Elizabeth A Sadowski
Journal:  Abdom Imaging       Date:  2015-10

Review 4.  MRI of malignant neoplasms of the uterine corpus and cervix.

Authors:  Evis Sala; Suzanne Wakely; Emma Senior; David Lomas
Journal:  AJR Am J Roentgenol       Date:  2007-06       Impact factor: 3.959

Review 5.  The added role of MR imaging in treatment stratification of patients with gynecologic malignancies: what the radiologist needs to know.

Authors:  Evis Sala; Andrea G Rockall; Susan J Freeman; Donald G Mitchell; Caroline Reinhold
Journal:  Radiology       Date:  2013-03       Impact factor: 11.105

6.  Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma.

Authors:  Margaret E McCusker; Timothy R Coté; Limin X Clegg; Fattaneh J Tavassoli
Journal:  Gynecol Oncol       Date:  2003-03       Impact factor: 5.482

7.  Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.

Authors:  Georgia A McCann; Christina E Boutsicaris; Megan M Preston; Floor J Backes; Eric L Eisenhauer; Jeffrey M Fowler; David E Cohn; Larry J Copeland; Ritu Salani; David M O'Malley
Journal:  Gynecol Oncol       Date:  2013-01-26       Impact factor: 5.482

8.  Usefulness of diffusion-weighted MR imaging in the evaluation of pulmonary lesions.

Authors:  Haidong Liu; Ying Liu; Tielian Yu; Ning Ye
Journal:  Eur Radiol       Date:  2009-10-28       Impact factor: 5.315

9.  Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.

Authors:  J-M Lee; K-B Lee; J-H Nam; S-Y Ryu; D-S Bae; J-T Park; S-C Kim; S-D Cha; K-R Kim; S-Y Song; S-B Kang
Journal:  Ann Oncol       Date:  2007-10-24       Impact factor: 32.976

10.  A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix.

Authors:  Samina Dongol; Yanhong Tai; Yi Shao; Jie Jiang; Beihua Kong
Journal:  Mol Clin Oncol       Date:  2013-09-25
View more
  4 in total

Review 1.  Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics.

Authors:  Tsukasa Saida; Akiko Sakata; Yumiko Oishi Tanaka; Hiroyuki Ochi; Toshitaka Ishiguro; Masafumi Sakai; Hiroaki Takahashi; Toyomi Satoh; Manabu Minami
Journal:  Korean J Radiol       Date:  2019-03       Impact factor: 3.500

Review 2.  Neuroendocrine Neoplasms of the Gynecologic Tract.

Authors:  Mayur Virarkar; Sai Swarupa Vulasala; Ajaykumar C Morani; Rebecca Waters; Dheeraj R Gopireddy; Sindhu Kumar; Priya Bhosale; Chandana Lall
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

Review 3.  Importance of tumor subtypes in cancer imaging.

Authors:  Ali Khader; Marta Braschi-Amirfarzan; Lacey J McIntosh; Babina Gosangi; Jeremy R Wortman; Christoph Wald; Richard Thomas
Journal:  Eur J Radiol Open       Date:  2022-07-26

4.  Neuroendocrine carcinoma of the cervix: a systematic review of the literature.

Authors:  Clemens B Tempfer; Iris Tischoff; Askin Dogan; Ziad Hilal; Beate Schultheis; Peter Kern; Günther A Rezniczek
Journal:  BMC Cancer       Date:  2018-05-04       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.